金融界9月27日消息，根据昭衍新药2024年中期报告，至2024年6月30日，首次公开发售前购股权及受限制股份奖励计划项下的尚未行使且尚未过期的购股权的A股股份总数为818,888股。其中，董事左从林、高大鹏、孙云霞以及姚大林尚未行使的购股权分别为37,632、11,760、11,760以及11,760股。首席财务官于爱水尚未行使的购股权为5,880股，其他员工的尚未行使购股权为740,096股。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.